Ladenburg Thalmann Financial Services Reiterates “Buy” Rating for Novavax (NVAX)
Novavax (NASDAQ:NVAX)‘s stock had its “buy” rating reiterated by equities researchers at Ladenburg Thalmann Financial Services in a note issued to investors on Thursday, The Fly reports. They currently have a $3.50 price target on the biopharmaceutical company’s stock. Ladenburg Thalmann Financial Services’ price objective suggests a potential upside of 63.55% from the stock’s previous close.
Several other research firms also recently weighed in on NVAX. B. Riley set a $10.00 price target on Novavax and gave the stock a “buy” rating in a research note on Thursday. Citigroup downgraded Novavax from a “buy” rating to a “neutral” rating and set a $1.00 price target for the company. in a research note on Tuesday, December 19th. S&P Equity Research dropped their price target on Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. BidaskClub upgraded Novavax from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 21st. Finally, Zacks Investment Research downgraded Novavax from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. Novavax has a consensus rating of “Hold” and an average price target of $3.11.
Novavax (NVAX) traded down $0.13 during mid-day trading on Thursday, reaching $2.14. The company’s stock had a trading volume of 17,390,000 shares, compared to its average volume of 11,750,000. Novavax has a 1-year low of $0.73 and a 1-year high of $2.75. The company has a quick ratio of 3.31, a current ratio of 3.31 and a debt-to-equity ratio of -4.28. The company has a market cap of $632.70, a P/E ratio of -3.15 and a beta of 2.49.
ILLEGAL ACTIVITY NOTICE: This article was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/ladenburg-thalmann-financial-services-reiterates-buy-rating-for-novavax-nvax/1905401.html.
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.